PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2017.46020185041164-1174Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib TreatmentJeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Changhttp://e-crt.org/upload/pdf/crt-2017-460.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2017.460, http://www.e-crt.org/upload/pdf/crt-2017-460.pdf
Technology in Cancer Research & Treatment10.1177/1533033820957030202019153303382095703PLEK2 Gene Upregulation Might Independently Predict Shorter Progression-Free Survival in Lung AdenocarcinomaWenqian Zhang, Tong Li, Bin Hu, Hui Lihttp://journals.sagepub.com/doi/pdf/10.1177/1533033820957030, http://journals.sagepub.com/doi/full-xml/10.1177/1533033820957030, http://journals.sagepub.com/doi/pdf/10.1177/1533033820957030
Cancer Treatment Reviews10.1016/j.ctrv.2014.11.004201541277-93A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemiaPiotr Ladyzynski, Maria Molik, Piotr Foltynskihttps://api.elsevier.com/content/article/PII:S030573721400190X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S030573721400190X?httpAccept=text/plain
The Lancet Respiratory Medicine10.1016/s2213-2600(17)30085-1201754251Osimertinib improves progression-free survival in NSCLCSheila Pinionhttps://api.elsevier.com/content/article/PII:S2213260017300851?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S2213260017300851?httpAccept=text/xml
The Lancet Oncology10.1016/s1470-2045(17)30893-82018191e10Osimertinib improves progression-free survival in NSCLCRobert Stirrupshttps://api.elsevier.com/content/article/PII:S1470204517308938?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1470204517308938?httpAccept=text/plain
Cancer Treatment Reviews10.1016/j.ctrv.2011.01.0022011377495-504Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpointSara A. Hurvitzhttps://api.elsevier.com/content/article/PII:S0305737211000041?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0305737211000041?httpAccept=text/plain
Neoplasia10.1593/neo.06838200793181-IN2Low Expression of ARHI Is Associated with Shorter Progression-Free Survival in Pancreatic Endocrine TumorsIrene Dalai, Edoardo Missiaglia, Stefano Barbi, Giovanni Butturini, Claudio Doglioni, Massimo Falconi, Aldo Scarpahttps://api.elsevier.com/content/article/PII:S1476558607800480?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1476558607800480?httpAccept=text/plain
Cancer Treatment and Research Communications10.1016/j.ctarc.2020.100259202025100259Prolonged survival without progression under crizotinib treatmentAhmet Gulmezhttps://api.elsevier.com/content/article/PII:S2468294220300940?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2468294220300940?httpAccept=text/plain
Hematological Oncology10.1002/hon.2438_77201735212-213PROGRESSION-FREE SURVIVAL FOLLOWING LENALIDOMIDE-BASED TREATMENT IS SIGNIFICANTLY LONGER IN EXTRAGASTRIC THAN IN GASTRIC MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA (MALT LYMPHOMA)B. Kiesewetter, M.E. Mayerhoefer, W. Dolak, J. Lukas, I. Simonitsch-Klupp, M. Radererhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhon.2438_77, http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2438_77/fullpdf
Cancers10.3390/cancers120204922020122492Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) LymphomaBarbara Kiesewetter, Ingrid Simonitsch-Klupp, Werner Dolak, Marius E. Mayerhoefer, Markus Radererhttps://www.mdpi.com/2072-6694/12/2/492/pdf